will buy Penumbra (PEN) for $14.5 billion, or $374 a share, the medtechs announced before the open. The move expand Boston Scientific's cardiovascular reach. Boston Sci shares fell before the open while Penumbra stock jumped. Penumbra specializes in mechanical thrombectomy and neurovascular…
Continue reading...